Abstracts tagged "Family studies and systemic lupus erythematosus (SLE)"

Abstract Number: 984 • 2017 ACR/ARHP Annual Meeting
Identification of Key Screening Characteristics for Systemic Lupus Erythematosus Natural History
Kendra A. Young¹, Melissa E. Munroe², Joel M. Guthridge³, Diane L. Kamen⁴, Gary S. Gilkeson⁵, Michael Weisman⁶, David Karp⁷, John B. Harley⁸, Daniel J. Wallace⁶, Judith A. James⁹ and Jill M. Norris¹⁰, ¹Epidemiology, University of Colorado Denver, Aurora, CO, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, OKC, OK, ⁴Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁵Department of Medicine, Medical University of South Carolina, Charleston, SC, ⁶Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA, ⁷Rheumatology, UT Southwestern Med Ctr, Dallas, TX, ⁸Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁰Department of Epidemiology, Colorado School of Public Health, Aurora, CO
Background/Purpose: A prospective study of preclinical SLE disease evolution is needed to help elucidate critical aspects of disease etiology and early pathogenesis, and to identify…
Abstract Number: 2634 • 2017 ACR/ARHP Annual Meeting
The Prevalence of Autoimmune Disease in Families of Patients with Systemic Lupus Erythematosus (SLE). a Single Centre Study
Oseme Etomi¹, Andrea Cove-Smith², Ravindra Rajakariar³, Myles J. Lewis^2,4,5,6, Angela Pakozdi² and Debasish Pyne², ¹heumatology Department, Barth Health NHS foundation trust, London, United Kingdom, ²Barts Lupus Centre, Barts Health NHS Trust, London, United Kingdom, ³Bart's Lupus Center, Barts Health NHS Foundation Trust, London, United Kingdom, ⁴Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom, ⁵Myles Lewis ([email protected]), London, United Kingdom, ⁶Rheumatology, Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
Background/Purpose: Studies to date have reported that up to 30% of lupus patient have a first degree relative with an autoimmune disorder (AD). The most…
Abstract Number: 2880 • 2014 ACR/ARHP Annual Meeting
Elevated Levels of Soluble Inflammatory Mediators and Lupus-Specific Connective Tissue Disease Questionnaire Scores Discern Unaffected First Degree Relatives of Lupus Patients from Unaffected Individuals Not Related to Lupus Patients
Melissa E. Munroe¹, Kendra A. Young², Jennifer Fessler³, Dustin Fife³, Diane L. Kamen⁴, Joel M. Guthridge³, Timothy B. Niewold⁵, Michael H. Weisman⁶, Mariko L. Ishimori⁶, Daniel J. Wallace⁷, David R. Karp⁸, John B. Harley⁹, Gary S. Gilkeson⁴, Jill M. Norris² and Judith A. James^10,11, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁵Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ⁹Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and select individuals for prevention trials. First-degree relatives (FDRs) of lupus patients…
Abstract Number: 2277 • 2012 ACR/ARHP Annual Meeting
Familial Aggregation and Heritability of Systemic Lupus Erythematosus in Taiwan: A Nationwide Population Study
Chang-Fu Kuo¹, Matthew J. Grainge², Lai-Chu See³, Kuang-Hui Yu⁴, Shue-Fen Luo⁴, Ana M. Valdes⁵, Hsiao-Chun Chang⁴, I-Jun Chou⁶, Weiya Zhang¹ and Michael Doherty⁷, ¹Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ²Division of Epidemiology and Public Health, School of Community Health Sciences, University of Nottingham, Nottingham, United Kingdom, ³Department of Public Health, College of Medicine, Chang Gung University, Taoyuan, Taiwan, ⁴Division of Rheumatology, Immunology and Allergy, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁵Dept of Twin Research and Genetic Epidemiology, St. Thomas' Hospital, King's College London, London, United Kingdom, ⁶Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁷Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom
Background/Purpose: The aims of the present study were to estimate relative risk (RR) of systemic lupus erythematosus (SLE) in individuals with affected relatives in comparison…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].